
Masato Hosokawa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8319417/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Development of a novel tau propagation mouse model endogenously expressing 3 and 4 repeat tau isoforms. Brain, 2022, 145, 349-361.	3.7	11
2	Development of an Organ-Directed Exosome-Based siRNA-Carrier Derived from Autologous Serum for Lung Metastases and Testing in the B16/BL6 Spontaneous Lung Metastasis Model. Pharmaceutics, 2022, 14, 815.	2.0	3
3	Therapeutic effect of anti-HMGB1 antibody in a mouse model of 4-h middle cerebral artery occlusion: comparison with tissue plasminogen activator. NeuroReport, 2022, 33, 297-303.	0.6	2
4	Early-life stress induces the development of Alzheimer's disease pathology via angiopathy. Experimental Neurology, 2021, 337, 113552.	2.0	17
5	LC–MS/MS assay for the investigation of acetylated Alpha-synuclein in serum from postmortem Alzheimer's disease pathology. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1181, 122885.	1.2	1
6	Tyrosine 136 phosphorylation of α-synuclein aggregates in the Lewy body dementia brain: involvement of serine 129 phosphorylation by casein kinase 2. Acta Neuropathologica Communications, 2021, 9, 182.	2.4	17
7	Effects of progranulin on the pathological conditions in experimental myocardial infarction model. Scientific Reports, 2020, 10, 11842.	1.6	10
8	Dextran sulphate-induced tau assemblies cause endogenous tau aggregation and propagation in wild-type mice. Brain Communications, 2020, 2, fcaa091.	1.5	6
9	$\hat{I}\pm$ -synuclein strains that cause distinct pathologies differentially inhibit proteasome. ELife, 2020, 9, .	2.8	45
10	Progranulin and Frontotemporal Lobar Degeneration. , 2019, , 35-69.		2
11	PGRN and Neurodegenerative Diseases Other Than FTLD. , 2019, , 71-84.		0
12	Progranulin haploinsufficiency reduces amyloid beta deposition in Alzheimer's disease model mice. Experimental Animals, 2018, 67, 63-70.	0.7	14
13	C9ORF72 dipeptide repeat poly-GA inclusions promote intracellular aggregation of phosphorylated TDP-43. Human Molecular Genetics, 2018, 27, 2658-2670.	1.4	39
14	Clinical features of the behavioural variant of frontotemporal dementia that are useful for predicting underlying pathological subtypes of frontotemporal lobar degeneration. Psychogeriatrics, 2018, 18, 307-312.	0.6	7
15	Progranulin regulates lysosomal function and biogenesis through acidification of lysosomes. Human Molecular Genetics, 2017, 26, ddx011.	1.4	110
16	Accumulation of multiple neurodegenerative disease-related proteins in familial frontotemporal lobar degeneration associated with granulin mutation. Scientific Reports, 2017, 7, 1513.	1.6	33
17	The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Science Translational Medicine, 2017, 9, .	5.8	182
18	Enhancement and regulation effect of myrcene on antibody response in immunization with ovalbumin and Ag85B in mice. Asian Pacific Journal of Allergy and Immunology, 2017, 34, 314-323.	0.2	3

MASATO HOSOKAWA

#	Article	IF	CITATIONS
19	Quantitative and combinatory determination of in situ phosphorylation of tau and its FTDP-17 mutants. Scientific Reports, 2016, 6, 33479.	1.6	21
20	P3â€300: Phosphorylated TAU and Alpha‣ynuclein Accumulation in Familial Granulin Mutation Cases. Alzheimer's and Dementia, 2016, 12, P956.	0.4	0
21	Chorea as a clinical feature of the basophilic inclusion body disease subtype of fused-in-sarcoma-associated frontotemporal lobar degeneration. Acta Neuropathologica Communications, 2016, 4, 36.	2.4	9
22	The Abundance of Nonphosphorylated Tau in Mouse and Human Tauopathy Brains Revealed by the Use of Phos-Tag Method. American Journal of Pathology, 2016, 186, 398-409.	1.9	20
23	An autopsied case of corticobasal degeneration showing severe cerebral atrophy over a protracted disease course of 16 years. Neuropathology, 2015, 35, 280-288.	0.7	2
24	Progranulin Reduction Is Associated With Increased Tau Phosphorylation in P301L Tau Transgenic Mice. Journal of Neuropathology and Experimental Neurology, 2015, 74, 158-165.	0.9	46
25	Differential diagnosis of amyotrophic lateral sclerosis from Guillain–Barré syndrome by quantitative determination of TDP-43 in cerebrospinal fluid. International Journal of Neuroscience, 2014, 124, 344-349.	0.8	26
26	Distinct pathways leading to TDP-43-induced cellular dysfunctions. Human Molecular Genetics, 2014, 23, 4345-4356.	1.4	30
27	Pathological alpha-synuclein propagates through neural networks. Acta Neuropathologica Communications, 2014, 2, 88.	2.4	203
28	Tau accumulation in the nucleus accumbens in tangle-predominant dementia. Acta Neuropathologica Communications, 2014, 2, 40.	2.4	29
29	Atypical FTLDâ€FUS associated with ALSâ€TDP: A case report. Neuropathology, 2013, 33, 83-86.	0.7	3
30	Pathological features of FTLD-FUS in a Japanese population: Analyses of nine cases. Journal of the Neurological Sciences, 2013, 335, 89-95.	0.3	6
31	Pyriproxyfen enhances the immunoglobulin G immune response in mice. Microbiology and Immunology, 2013, 57, 316-322.	0.7	4
32	Microsomal prostaglandin E synthaseâ€1 is induced in alzheimer's disease and its deletion mitigates alzheimer's diseaseâ€like pathology in a mouse model. Journal of Neuroscience Research, 2013, 91, 909-919.	1.3	39
33	Prion-like spreading of pathological α-synuclein in brain. Brain, 2013, 136, 1128-1138.	3.7	691
34	Localization of fused in sarcoma (FUS) protein to the post-synaptic density in the brain. Acta Neuropathologica, 2012, 124, 383-394.	3.9	40
35	Molecular analysis and biochemical classification of TDP-43 proteinopathy. Brain, 2012, 135, 3380-3391.	3.7	95
36	Familial ALS with FUS P525L mutation: two Japanese sisters with multiple systems involvement. Journal of the Neurological Sciences, 2012, 323, 85-92.	0.3	33

MASATO HOSOKAWA

#	ARTICLE	IF	CITATIONS
37	Longâ€ŧerm oral intake of aluminium or zinc does not accelerate Alzheimer pathology in AβPP and AβPP/tau transgenic mice. Neuropathology, 2012, 32, 390-397.	0.7	33
38	Methylene Blue Reduced Abnormal Tau Accumulation in P301L Tau Transgenic Mice. PLoS ONE, 2012, 7, e52389.	1.1	79
39	Phosphorylated and cleaved TDP-43 in ALS, FTLD and other neurodegenerative disorders and in cellular models of TDP-43 proteinopathy. Neuropathology, 2010, 30, 170-181.	0.7	109
40	Novel virus discovery in field-collected mosquito larvae using an improved system for rapid determination of viral RNA sequences (RDV ver4.0). Archives of Virology, 2009, 154, 153-158.	0.9	35
41	A chemical chaperone, sodium 4-phenylbutyric acid, attenuates the pathogenic potency in human α-synuclein A30P + A53T transgenic mice. Parkinsonism and Related Disorders, 2009, 15, 649-654.	1.1	72
42	Natural killer cells of Parkinson's disease patients are set up for activation: A possible role for innate immunity in the pathogenesis of this disease. Parkinsonism and Related Disorders, 2008, 14, 46-51.	1.1	59
43	Comparative study to elucidate the mechanism underlying the difference in airway hyperresponsiveness between two mouse strains. International Immunopharmacology, 2007, 7, 1852-1861.	1.7	16
44	Human IgM Monoclonal Antibodies Reactive with HIVâ€1â€Infected Cells Generated Using a Transâ€Chromosome Mouse. Microbiology and Immunology, 2005, 49, 447-459.	0.7	2
45	Human oligodendroglial cells express low levels of C1 inhibitor and membrane cofactor protein mRNAs. Journal of Neuroinflammation, 2004, 1, 17.	3.1	6
46	Inhibition of HIV-1 infection in cells expressing an artificial complementary peptide. Biochemical and Biophysical Research Communications, 2004, 324, 236-240.	1.0	6
47	Familial British dementia: colocalization of furin and ABri amyloid. Acta Neuropathologica, 2003, 106, 278-284.	3.9	12
48	Expression of complement messenger RNAs and proteins by human oligodendroglial cells. Clia, 2003, 42, 417-423.	2.5	83